82_FR_54576 82 FR 54355 - Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notification for a New Dietary Ingredient

82 FR 54355 - Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notification for a New Dietary Ingredient

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 82, Issue 221 (November 17, 2017)

Page Range54355-54357
FR Document2017-24925

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the procedure by which a manufacturer or distributor of a new dietary ingredient or of a dietary supplement containing a new dietary ingredient is to submit to FDA information upon which it has based its conclusion that a dietary supplement containing the new dietary ingredient will reasonably be expected to be safe.

Federal Register, Volume 82 Issue 221 (Friday, November 17, 2017)
[Federal Register Volume 82, Number 221 (Friday, November 17, 2017)]
[Notices]
[Pages 54355-54357]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-24925]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0878]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Premarket Notification for a New Dietary Ingredient

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
an opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(PRA), Federal Agencies are required to publish notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, and 
to allow 60 days for public comment in response to the notice. This 
notice solicits comments on the procedure by which a manufacturer or 
distributor of a new dietary ingredient or of a dietary supplement 
containing a new dietary ingredient is to submit to FDA information 
upon which it has based its conclusion that a dietary supplement 
containing the new dietary ingredient will reasonably be expected to be 
safe.

DATES: Submit either electronic or written comments on the collection 
of information by January 16, 2018.

ADDRESSES: You may submit comments as follows. Please note that late, 
untimely filed comments will not be considered. Electronic comments 
must be submitted on or before January 16, 2018. The https://www.regulations.gov electronic filing system will accept comments until 
midnight Eastern Time at the end of January 16, 2018. Comments received 
by mail/hand delivery/courier (for written/paper submissions) will be 
considered timely if they are postmarked or the delivery service 
acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2013-N-0878 for ``Premarket Notification for a New Dietary 
Ingredient.'' Received comments, those filed in a timely manner (see 
ADDRESSES), will be placed in the docket and, except for those 
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. 
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Ila Mizrachi, Office of Operations, 
Food and Drug Administration, Three White Flint North, 10A-12M, 11601 
Landsdown St., North Bethesda, MD

[[Page 54356]]

20852, 301-796-7726, [email protected].

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
Agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes Agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal Agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, 
before submitting the collection to OMB for approval. To comply with 
this requirement, FDA is publishing notice of the proposed collection 
of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Premarket Notification for a New Dietary Ingredient--21 CFR 190.6

OMB Control Number 0910-0330--Extension

    This information collection supports Agency regulations. 
Specifically, section 413(a) of the Federal Food, Drug, and Cosmetic 
Act (the FD&C Act) (21 U.S.C. 350b(a)) provides that at least 75 days 
before the introduction or delivery for introduction into interstate 
commerce of a dietary supplement that contains a new dietary 
ingredient, the manufacturer or distributor of the dietary supplement 
or of the new dietary ingredient is to submit to FDA (as delegate for 
the Secretary of Health and Human Services) information upon which the 
manufacturer or distributor has based its conclusion that a dietary 
supplement containing the new dietary ingredient will reasonably be 
expected to be safe. FDA's implementing regulation, Sec.  190.6 (21 CFR 
190.6), requires this information to be submitted to the Office of 
Nutrition, Labeling, and Dietary Supplements (ONLDS) in the form of a 
notification. Under Sec.  190.6(b), the notification must include the 
following: (1) The name and complete address of the manufacturer or 
distributor; (2) the name of the new dietary ingredient; (3) a 
description of the dietary supplement(s) that contain the new dietary 
ingredient, including the level of the new dietary ingredient in the 
dietary supplement and the dietary supplement's conditions of use; (4) 
the history of use or other evidence of safety establishing that the 
new dietary ingredient will reasonably be expected to be safe when used 
under the conditions recommended or suggested in the labeling of the 
dietary supplement; and (5) the signature of a responsible person 
designated by the manufacturer or distributor.
    These premarket notification requirements are designed to enable us 
to monitor the introduction into the marketplace of new dietary 
ingredients and dietary supplements that contain new dietary 
ingredients in order to protect consumers from ingredients and products 
whose safety is unknown. FDA uses the information collected in new 
dietary ingredient notifications to evaluate the safety of new dietary 
ingredients in dietary supplements and to support regulatory action 
against ingredients and products that are potentially unsafe.
    FDA has developed an electronic portal that respondents may use to 
electronically submit their notifications to ONLDS via FDA Unified 
Registration and Listing System (FURLS). Firms that prefer to submit a 
paper notification in a format of their own choosing still have the 
option to do so; however, Form FDA 3880 prompts a submitter to input 
the elements of a new dietary ingredient notification (NDIN) in a 
standard format and helps the respondent organize its NDIN to focus on 
the information needed for FDA's safety review. Safety information may 
be submitted via a supplemental form entitled ``New Dietary Ingredient 
Safety Information.'' This form provides a standard format to describe 
the history of use or other evidence of safety on which the 
manufacturer or distributor bases its conclusion that the new dietary 
ingredient is reasonably expected to be safe under the conditions of 
use recommended or suggested in the labeling of the dietary supplement, 
as well as related identity information that is necessary to 
demonstrate safety by showing that the new dietary ingredient and 
dietary supplement(s) that are the subject of the notification are the 
same or similar to the ingredients and products for which safety data 
and information have been provided. We invite comment on Form FDA 3880 
and the supplemental safety information form, which may be found on our 
Web site at https://www.fda.gov/Food/DietarySupplements/NewDietaryIngredientsNotificationProcess/default.htm.
    Description of Respondents: The respondents to this collection of 
information are manufacturers and distributors in the dietary 
supplement industry; specifically, firms that manufacture or distribute 
new dietary ingredients or dietary supplements that contain a new 
dietary ingredient.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                         Number of                      Average  burden
                           21 CFR section                               Number of      responses per     Total annual    per  response     Total hours
                                                                       respondents       respondent       responses        (in hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
190.6; Dietary Supplements.........................................              55                1               55               20            1,100
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

    We have made no adjustments to the currently approved burden 
estimate for the information collection. While we have received 
previous comments suggesting our burden estimate may be too low, the 
comments did not discuss the basis for such a conclusion. We therefore 
specifically invite those commenters offering an alternative

[[Page 54357]]

burden estimate to include the methodology or reasoning used to do so.
    Based on our experience with the information collection over the 
past 3 years, we estimate that 55 respondents will submit 1 premarket 
notification each. We estimate that extracting and summarizing the 
relevant information from what exists in the company's files and 
presenting it in a format that meets the requirements of Sec.  190.6 
will take approximately 20 hours of work per notification. We have 
carefully considered the burden associated with the premarket 
notification requirement and believe that estimates greater than 20 
hours are likely to include burden associated with researching and 
generating safety data for a new dietary ingredient. We also believe 
that the burden of the premarket notification requirement on industry 
is minimal and reasonable because we are requesting only safety and 
identity information that the manufacturer or distributor should 
already have developed to satisfy itself that a dietary supplement 
containing a new dietary ingredient is in compliance with the FD&C Act. 
Under section 413(a)(2) of the FD&C Act, a dietary supplement that 
contains a new dietary ingredient is deemed to be adulterated unless 
there is a history of use or other evidence of safety establishing that 
the new dietary ingredient will reasonably be expected to be safe under 
the conditions of use recommended or suggested in the labeling of the 
dietary supplement. This requirement is separate from and additional to 
the requirement to submit a premarket notification for the new dietary 
ingredient. FDA's regulation on new dietary ingredient notifications, 
Sec.  190.6(a), requires the manufacturer or distributor of the dietary 
supplement or of the new dietary ingredient to submit to FDA the 
information that forms the basis for its conclusion that a dietary 
supplement containing the new dietary ingredient will reasonably be 
expected to be safe. Thus, Sec.  190.6 only requires the manufacturer 
or distributor to extract and summarize information that should have 
already been developed to meet the safety requirement in section 
413(a)(2) of the FD&C Act.

    Dated: November 9, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-24925 Filed 11-16-17; 8:45 am]
BILLING CODE 4164-01-P



                                                                            Federal Register / Vol. 82, No. 221 / Friday, November 17, 2017 / Notices                                          54355

                                                scheduled presentation times. Persons                   information upon which it has based its               identified, as confidential, if submitted
                                                registered to speak should check in                     conclusion that a dietary supplement                  as detailed in ‘‘Instructions.’’
                                                before the workshops and are                            containing the new dietary ingredient                    Instructions: All submissions received
                                                encouraged to arrive early to ensure                    will reasonably be expected to be safe.               must include the Docket No. FDA–
                                                their designated order of presentation.                 DATES: Submit either electronic or                    2013–N–0878 for ‘‘Premarket
                                                Participants who are not present when                   written comments on the collection of                 Notification for a New Dietary
                                                called may not be permitted to speak at                 information by January 16, 2018.                      Ingredient.’’ Received comments, those
                                                a later time. An agenda will be made                    ADDRESSES: You may submit comments                    filed in a timely manner (see
                                                available at least 3 days before each                   as follows. Please note that late,                    ADDRESSES), will be placed in the docket
                                                workshop at https://www.fda.gov/                        untimely filed comments will not be                   and, except for those submitted as
                                                Drugs/NewsEvents/ucm582091.htm.                         considered. Electronic comments must                  ‘‘Confidential Submissions,’’ publicly
                                                FDA may also post specific questions                    be submitted on or before January 16,                 viewable at https://www.regulations.gov
                                                for consideration at the meeting Web                    2018. The https://www.regulations.gov                 or at the Dockets Management Staff
                                                page; these will be made available at                   electronic filing system will accept                  between 9 a.m. and 4 p.m., Monday
                                                least 3 days before each workshop at                    comments until midnight Eastern Time                  through Friday.
                                                https://www.fda.gov/Drugs/NewsEvents/                   at the end of January 16, 2018.                          • Confidential Submissions—To
                                                ucm582091.htm.                                          Comments received by mail/hand                        submit a comment with confidential
                                                   Streaming Webcast and Video of the                   delivery/courier (for written/paper                   information that you do not wish to be
                                                Public Workshops: These public                          submissions) will be considered timely                made publicly available, submit your
                                                workshops will be webcast; the URL                      if they are postmarked or the delivery                comments only as a written/paper
                                                will be posted at https://www.fda.gov/                  service acceptance receipt is on or                   submission. You should submit two
                                                Drugs/NewsEvents/ucm582091.htm at                       before that date.                                     copies total. One copy will include the
                                                least 1 day before each workshop. A
                                                                                                        Electronic Submissions                                information you claim to be confidential
                                                video record of the public workshops
                                                                                                                                                              with a heading or cover note that states
                                                will be available at the same Web site                    Submit electronic comments in the                   ‘‘THIS DOCUMENT CONTAINS
                                                address for 1 year.                                     following way:                                        CONFIDENTIAL INFORMATION.’’ The
                                                  Dated: November 13, 2017.                               • Federal eRulemaking Portal:                       Agency will review this copy, including
                                                Leslie Kux,                                             https://www.regulations.gov. Follow the               the claimed confidential information, in
                                                Associate Commissioner for Policy.                      instructions for submitting comments.                 its consideration of comments. The
                                                [FR Doc. 2017–24918 Filed 11–16–17; 8:45 am]            Comments submitted electronically,                    second copy, which will have the
                                                BILLING CODE 4164–01–P
                                                                                                        including attachments, to https://                    claimed confidential information
                                                                                                        www.regulations.gov will be posted to                 redacted/blacked out, will be available
                                                                                                        the docket unchanged. Because your                    for public viewing and posted on
                                                DEPARTMENT OF HEALTH AND                                comment will be made public, you are                  https://www.regulations.gov. Submit
                                                HUMAN SERVICES                                          solely responsible for ensuring that your             both copies to the Dockets Management
                                                                                                        comment does not include any                          Staff. If you do not wish your name and
                                                Food and Drug Administration                            confidential information that you or a                contact information to be made publicly
                                                                                                        third party may not wish to be posted,                available, you can provide this
                                                [Docket No. FDA–2013–N–0878]
                                                                                                        such as medical information, your or                  information on the cover sheet and not
                                                Agency Information Collection                           anyone else’s Social Security number, or              in the body of your comments and you
                                                Activities; Proposed Collection;                        confidential business information, such               must identify this information as
                                                Comment Request; Premarket                              as a manufacturing process. Please note               ‘‘confidential.’’ Any information marked
                                                Notification for a New Dietary                          that if you include your name, contact                as ‘‘confidential’’ will not be disclosed
                                                Ingredient                                              information, or other information that                except in accordance with 21 CFR 10.20
                                                                                                        identifies you in the body of your                    and other applicable disclosure law. For
                                                AGENCY:    Food and Drug Administration,                comments, that information will be                    more information about FDA’s posting
                                                HHS.                                                    posted on https://www.regulations.gov.                of comments to public dockets, see 80
                                                ACTION:   Notice.                                         • If you want to submit a comment                   FR 56469, September 18, 2015, or access
                                                                                                        with confidential information that you                the information at: https://www.gpo.gov/
                                                SUMMARY:   The Food and Drug                            do not wish to be made available to the               fdsys/pkg/FR-2015-09-18/pdf/2015-
                                                Administration (FDA or Agency) is                       public, submit the comment as a                       23389.pdf.
                                                announcing an opportunity for public                    written/paper submission and in the                      Docket: For access to the docket to
                                                comment on the proposed collection of                   manner detailed (see ‘‘Written/Paper                  read background documents or the
                                                certain information by the Agency.                      Submissions’’ and ‘‘Instructions’’).                  electronic and written/paper comments
                                                Under the Paperwork Reduction Act of
                                                                                                        Written/Paper Submissions                             received, go to https://
                                                1995 (PRA), Federal Agencies are
                                                                                                                                                              www.regulations.gov and insert the
                                                required to publish notice in the                         Submit written/paper submissions as
                                                                                                                                                              docket number, found in brackets in the
                                                Federal Register concerning each                        follows:
                                                                                                                                                              heading of this document, into the
                                                proposed collection of information,                       • Mail/Hand delivery/Courier (for
                                                                                                                                                              ‘‘Search’’ box and follow the prompts
                                                including each proposed extension of an                 written/paper submissions): Dockets
                                                                                                                                                              and/or go to the Dockets Management
                                                existing collection of information, and                 Management Staff (HFA–305), Food and
sradovich on DSK3GMQ082PROD with NOTICES




                                                                                                                                                              Staff, 5630 Fishers Lane, Rm. 1061,
                                                to allow 60 days for public comment in                  Drug Administration, 5630 Fishers
                                                                                                                                                              Rockville, MD 20852.
                                                response to the notice. This notice                     Lane, Rm. 1061, Rockville, MD 20852.
                                                solicits comments on the procedure by                     • For written/paper comments                        FOR FURTHER INFORMATION CONTACT:   Ila
                                                which a manufacturer or distributor of                  submitted to the Dockets Management                   Mizrachi, Office of Operations, Food
                                                a new dietary ingredient or of a dietary                Staff, FDA will post your comment, as                 and Drug Administration, Three White
                                                supplement containing a new dietary                     well as any attachments, except for                   Flint North, 10A–12M, 11601
                                                ingredient is to submit to FDA                          information submitted, marked and                     Landsdown St., North Bethesda, MD


                                           VerDate Sep<11>2014   18:32 Nov 16, 2017   Jkt 244001   PO 00000   Frm 00040   Fmt 4703   Sfmt 4703   E:\FR\FM\17NON1.SGM   17NON1


                                                54356                           Federal Register / Vol. 82, No. 221 / Friday, November 17, 2017 / Notices

                                                20852, 301–796–7726, PRAStaff@                                413(a) of the Federal Food, Drug, and                 ingredients and products that are
                                                fda.hhs.gov.                                                  Cosmetic Act (the FD&C Act) (21 U.S.C.                potentially unsafe.
                                                SUPPLEMENTARY INFORMATION: Under the                          350b(a)) provides that at least 75 days                  FDA has developed an electronic
                                                PRA (44 U.S.C. 3501–3520), Federal                            before the introduction or delivery for               portal that respondents may use to
                                                Agencies must obtain approval from the                        introduction into interstate commerce of              electronically submit their notifications
                                                Office of Management and Budget                               a dietary supplement that contains a                  to ONLDS via FDA Unified Registration
                                                (OMB) for each collection of                                  new dietary ingredient, the                           and Listing System (FURLS). Firms that
                                                information they conduct or sponsor.                          manufacturer or distributor of the                    prefer to submit a paper notification in
                                                ‘‘Collection of information’’ is defined                      dietary supplement or of the new                      a format of their own choosing still have
                                                in 44 U.S.C. 3502(3) and 5 CFR                                dietary ingredient is to submit to FDA                the option to do so; however, Form FDA
                                                1320.3(c) and includes Agency requests                        (as delegate for the Secretary of Health              3880 prompts a submitter to input the
                                                or requirements that members of the                           and Human Services) information upon                  elements of a new dietary ingredient
                                                                                                              which the manufacturer or distributor                 notification (NDIN) in a standard format
                                                public submit reports, keep records, or
                                                                                                              has based its conclusion that a dietary               and helps the respondent organize its
                                                provide information to a third party.
                                                                                                              supplement containing the new dietary                 NDIN to focus on the information
                                                Section 3506(c)(2)(A) of the PRA (44
                                                                                                              ingredient will reasonably be expected                needed for FDA’s safety review. Safety
                                                U.S.C. 3506(c)(2)(A)) requires Federal
                                                                                                              to be safe. FDA’s implementing                        information may be submitted via a
                                                Agencies to provide a 60-day notice in
                                                                                                              regulation, § 190.6 (21 CFR 190.6),                   supplemental form entitled ‘‘New
                                                the Federal Register concerning each
                                                                                                              requires this information to be                       Dietary Ingredient Safety Information.’’
                                                proposed collection of information,
                                                                                                              submitted to the Office of Nutrition,                 This form provides a standard format to
                                                including each proposed extension of an
                                                                                                              Labeling, and Dietary Supplements                     describe the history of use or other
                                                existing collection of information,
                                                                                                              (ONLDS) in the form of a notification.                evidence of safety on which the
                                                before submitting the collection to OMB                       Under § 190.6(b), the notification must
                                                for approval. To comply with this                                                                                   manufacturer or distributor bases its
                                                                                                              include the following: (1) The name and               conclusion that the new dietary
                                                requirement, FDA is publishing notice                         complete address of the manufacturer or
                                                of the proposed collection of                                                                                       ingredient is reasonably expected to be
                                                                                                              distributor; (2) the name of the new                  safe under the conditions of use
                                                information set forth in this document.                       dietary ingredient; (3) a description of
                                                   With respect to the following                                                                                    recommended or suggested in the
                                                                                                              the dietary supplement(s) that contain
                                                collection of information, FDA invites                                                                              labeling of the dietary supplement, as
                                                                                                              the new dietary ingredient, including
                                                comments on these topics: (1) Whether                                                                               well as related identity information that
                                                                                                              the level of the new dietary ingredient
                                                the proposed collection of information                                                                              is necessary to demonstrate safety by
                                                                                                              in the dietary supplement and the
                                                is necessary for the proper performance                                                                             showing that the new dietary ingredient
                                                                                                              dietary supplement’s conditions of use;
                                                of FDA’s functions, including whether                                                                               and dietary supplement(s) that are the
                                                                                                              (4) the history of use or other evidence
                                                the information will have practical                                                                                 subject of the notification are the same
                                                                                                              of safety establishing that the new
                                                utility; (2) the accuracy of FDA’s                                                                                  or similar to the ingredients and
                                                                                                              dietary ingredient will reasonably be
                                                estimate of the burden of the proposed                                                                              products for which safety data and
                                                                                                              expected to be safe when used under the
                                                collection of information, including the                                                                            information have been provided. We
                                                                                                              conditions recommended or suggested
                                                validity of the methodology and                                                                                     invite comment on Form FDA 3880 and
                                                                                                              in the labeling of the dietary
                                                assumptions used; (3) ways to enhance                                                                               the supplemental safety information
                                                                                                              supplement; and (5) the signature of a
                                                the quality, utility, and clarity of the                                                                            form, which may be found on our Web
                                                                                                              responsible person designated by the
                                                information to be collected; and (4)                                                                                site at https://www.fda.gov/Food/
                                                                                                              manufacturer or distributor.
                                                ways to minimize the burden of the                              These premarket notification                        DietarySupplements/
                                                collection of information on                                  requirements are designed to enable us                NewDietaryIngredients
                                                respondents, including through the use                        to monitor the introduction into the                  NotificationProcess/default.htm.
                                                of automated collection techniques,                           marketplace of new dietary ingredients                   Description of Respondents: The
                                                when appropriate, and other forms of                          and dietary supplements that contain                  respondents to this collection of
                                                information technology.                                       new dietary ingredients in order to                   information are manufacturers and
                                                Premarket Notification for a New                              protect consumers from ingredients and                distributors in the dietary supplement
                                                Dietary Ingredient—21 CFR 190.6                               products whose safety is unknown. FDA                 industry; specifically, firms that
                                                                                                              uses the information collected in new                 manufacture or distribute new dietary
                                                OMB Control Number 0910–0330—                                 dietary ingredient notifications to                   ingredients or dietary supplements that
                                                Extension                                                     evaluate the safety of new dietary                    contain a new dietary ingredient.
                                                  This information collection supports                        ingredients in dietary supplements and                   FDA estimates the burden of this
                                                Agency regulations. Specifically, section                     to support regulatory action against                  collection of information as follows:

                                                                                                    TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
                                                                                                                                                                                        Average
                                                                                                                                                 Number of
                                                                                                                               Number of                          Total annual        burden per
                                                                           21 CFR section                                                      responses per                                        Total hours
                                                                                                                              respondents                          responses           response
                                                                                                                                                 respondent                            (in hours)
sradovich on DSK3GMQ082PROD with NOTICES




                                                190.6; Dietary Supplements ................................................       55                   1               55                 20          1,100
                                                   1 There   are no capital costs or operating and maintenance costs associated with this collection of information.


                                                  We have made no adjustments to the                          have received previous comments                       the basis for such a conclusion. We
                                                currently approved burden estimate for                        suggesting our burden estimate may be                 therefore specifically invite those
                                                the information collection. While we                          too low, the comments did not discuss                 commenters offering an alternative



                                           VerDate Sep<11>2014     18:32 Nov 16, 2017     Jkt 244001    PO 00000    Frm 00041   Fmt 4703   Sfmt 4703   E:\FR\FM\17NON1.SGM   17NON1


                                                                            Federal Register / Vol. 82, No. 221 / Friday, November 17, 2017 / Notices                                          54357

                                                burden estimate to include the                          DEPARTMENT OF HEALTH AND                              comment does not include any
                                                methodology or reasoning used to do so.                 HUMAN SERVICES                                        confidential information that you or a
                                                   Based on our experience with the                                                                           third party may not wish to be posted,
                                                                                                        Food and Drug Administration                          such as medical information, your or
                                                information collection over the past 3
                                                                                                                                                              anyone else’s Social Security number, or
                                                years, we estimate that 55 respondents                  [Docket No. FDA–2014–D–0313]
                                                                                                                                                              confidential business information, such
                                                will submit 1 premarket notification
                                                                                                        Agency Information Collection                         as a manufacturing process. Please note
                                                each. We estimate that extracting and                                                                         that if you include your name, contact
                                                summarizing the relevant information                    Activities; Proposed Collection;
                                                                                                        Comment Request; Guidance for                         information, or other information that
                                                from what exists in the company’s files                                                                       identifies you in the body of your
                                                                                                        Industry, Researchers, Patient Groups,
                                                and presenting it in a format that meets                                                                      comments, that information will be
                                                                                                        and Food and Drug Administration
                                                the requirements of § 190.6 will take                                                                         posted on https://www.regulations.gov.
                                                                                                        Staff on Meetings With the Office of
                                                approximately 20 hours of work per
                                                                                                        Orphan Products Development                             • If you want to submit a comment
                                                notification. We have carefully                                                                               with confidential information that you
                                                considered the burden associated with                   AGENCY:    Food and Drug Administration,              do not wish to be made available to the
                                                the premarket notification requirement                  HHS.                                                  public, submit the comment as a
                                                and believe that estimates greater than                 ACTION:   Notice.                                     written/paper submission and in the
                                                20 hours are likely to include burden                                                                         manner detailed (see ‘‘Written/Paper
                                                associated with researching and                         SUMMARY:   The Food and Drug                          Submissions’’ and ‘‘Instructions’’).
                                                generating safety data for a new dietary                Administration (FDA or Agency) is
                                                                                                                                                              Written/Paper Submissions
                                                ingredient. We also believe that the                    announcing an opportunity for public
                                                                                                        comment on the proposed collection of                    Submit written/paper submissions as
                                                burden of the premarket notification
                                                                                                        certain information by the Agency.                    follows:
                                                requirement on industry is minimal and                                                                           • Mail/Hand delivery/Courier (for
                                                                                                        Under the Paperwork Reduction Act of
                                                reasonable because we are requesting                                                                          written/paper submissions): Dockets
                                                                                                        1995 (PRA), Federal Agencies are
                                                only safety and identity information that                                                                     Management Staff (HFA–305), Food and
                                                                                                        required to publish notice in the
                                                the manufacturer or distributor should                                                                        Drug Administration, 5630 Fishers
                                                                                                        Federal Register concerning each
                                                already have developed to satisfy itself                proposed collection of information,                   Lane, Rm. 1061, Rockville, MD 20852.
                                                that a dietary supplement containing a                  including each proposed extension of an                  • For written/paper comments
                                                new dietary ingredient is in compliance                 existing collection of information, and               submitted to the Dockets Management
                                                with the FD&C Act. Under section                        to allow 60 days for public comment in                Staff, FDA will post your comment, as
                                                413(a)(2) of the FD&C Act, a dietary                    response to the notice. This notice                   well as any attachments, except for
                                                supplement that contains a new dietary                  solicits comments on the Guidance for                 information submitted, marked and
                                                ingredient is deemed to be adulterated                  Industry, Researchers, Patient Groups,                identified, as confidential, if submitted
                                                unless there is a history of use or other               and FDA Staff on Meetings with the                    as detailed in ‘‘Instructions.’’
                                                evidence of safety establishing that the                Office of Orphan Products                                Instructions: All submissions received
                                                new dietary ingredient will reasonably                  Development.                                          must include the Docket No. FDA–
                                                be expected to be safe under the                                                                              2014–D–0313 for ‘‘Agency Information
                                                                                                        DATES:  Submit either electronic or                   Collection Activities; Proposed
                                                conditions of use recommended or                        written comments on the collection of                 Collection; Comment Request; Guidance
                                                suggested in the labeling of the dietary                information by January 16, 2018.                      for Industry, Researchers, Patient
                                                supplement. This requirement is
                                                                                                        ADDRESSES: You may submit comments                    Groups, and Food and Drug
                                                separate from and additional to the
                                                                                                        as follows. Please note that late,                    Administration Staff on Meetings with
                                                requirement to submit a premarket                       untimely filed comments will not be                   the Office of Orphan Products
                                                notification for the new dietary                        considered. Electronic comments must                  Development.’’ Received comments,
                                                ingredient. FDA’s regulation on new                     be submitted on or before January 16,                 those filed in a timely manner (see
                                                dietary ingredient notifications,                       2018. The https://www.regulations.gov                 ADDRESSES), will be placed in the docket
                                                § 190.6(a), requires the manufacturer or                electronic filing system will accept                  and, except for those submitted as
                                                distributor of the dietary supplement or                comments until midnight Eastern Time                  ‘‘Confidential Submissions,’’ publicly
                                                of the new dietary ingredient to submit                 at the end of January 16, 2018.                       viewable at https://www.regulations.gov
                                                to FDA the information that forms the                   Comments received by mail/hand                        or at the Dockets Management Staff
                                                basis for its conclusion that a dietary                 delivery/courier (for written/paper                   between 9 a.m. and 4 p.m., Monday
                                                supplement containing the new dietary                   submissions) will be considered timely                through Friday.
                                                ingredient will reasonably be expected                  if they are postmarked or the delivery                   • Confidential Submissions—To
                                                to be safe. Thus, § 190.6 only requires                 service acceptance receipt is on or                   submit a comment with confidential
                                                the manufacturer or distributor to                      before that date.                                     information that you do not wish to be
                                                extract and summarize information that                                                                        made publicly available, submit your
                                                                                                        Electronic Submissions                                comments only as a written/paper
                                                should have already been developed to
                                                meet the safety requirement in section                    Submit electronic comments in the                   submission. You should submit two
                                                413(a)(2) of the FD&C Act.                              following way:                                        copies total. One copy will include the
                                                                                                          • Federal eRulemaking Portal:                       information you claim to be confidential
                                                  Dated: November 9, 2017.                              https://www.regulations.gov. Follow the               with a heading or cover note that states
sradovich on DSK3GMQ082PROD with NOTICES




                                                Anna K. Abram,                                          instructions for submitting comments.                 ‘‘THIS DOCUMENT CONTAINS
                                                Deputy Commissioner for Policy, Planning,               Comments submitted electronically,                    CONFIDENTIAL INFORMATION.’’ The
                                                Legislation, and Analysis.                              including attachments, to https://                    Agency will review this copy, including
                                                [FR Doc. 2017–24925 Filed 11–16–17; 8:45 am]            www.regulations.gov will be posted to                 the claimed confidential information, in
                                                BILLING CODE 4164–01–P                                  the docket unchanged. Because your                    its consideration of comments. The
                                                                                                        comment will be made public, you are                  second copy, which will have the
                                                                                                        solely responsible for ensuring that your             claimed confidential information


                                           VerDate Sep<11>2014   18:32 Nov 16, 2017   Jkt 244001   PO 00000   Frm 00042   Fmt 4703   Sfmt 4703   E:\FR\FM\17NON1.SGM   17NON1



Document Created: 2017-11-17 05:15:16
Document Modified: 2017-11-17 05:15:16
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
DatesSubmit either electronic or written comments on the collection of information by January 16, 2018.
ContactIla Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, [email protected]
FR Citation82 FR 54355 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR